KKR to acquire Healthium Medtech from Apax Partners
In a significant transaction, KKR, the global investment firm, has announced definitive agreements to acquire Healthium Medtech Ltd. from an affiliate of Apax Partners LLP. Funds managed by KKR will purchase a controlling interest in Healthium, a leading Indian medical devices company. Financial details of the acquisition remain undisclosed, and the transaction is expected to close in the third quarter of 2024, pending regulatory approvals.
Key Aspects of the Acquisition
– Deal Structure: The acquisition will be carried out by a special purpose vehicle managed by KKR, marking another strategic investment in Asia-Pacific healthcare.
– Growth Potential: KKR aims to leverage its global network to scale Healthium through organic and inorganic strategies.
– Global Portfolio: KKR’s existing healthcare investments in Asia include notable companies like JB, Max Healthcare, and Gland Pharma.
KKR to acquire Healthium Medtech from Apax Partners LLP
Transition of Healthium under Apax Partners
Under Apax’s ownership since 2018, Healthium transformed from a domestic player into a global medical devices leader. Apax strengthened Healthium’s management team and expanded its product lines to include wound closure, arthroscopy, and advanced wound care. The company also expanded its market reach from 50 to over 90 countries.
Leadership Comments
– Akshay Tanna, KKR: “We look forward to leveraging our global network and healthcare expertise to accelerate its growth in this fast-growing sector.”
– Steven Dyson, Apax: “We are proud to have supported Healthium on its growth journey… to become the leading medical technology player in India.”
– Anish Bafna, Healthium CEO: “We look forward to our next phase of growth with KKR’s support, being able to leverage their global platform.”
Advisory Support
– Apax and Healthium received financial advice from Jefferies LLC, with Kirkland & Ellis LLP providing legal counsel.
– KKR was advised by Moelis & Company, Simpson Thacher & Bartlett, and AZB & Partners.